Seroatlas · Human Serome Atlas

AKR1C2

Aldo-keto reductase family 1 member C2

Also known as: AK1C2_HUMAN, BABP, DD, DD2, DDH2, HAKRD, MCDR2, TDD

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
P52895
Gene
AKR1C2
Ensembl
ENSG00000151632
Chromosome
10
Canonical length
323 aa
Protein class
Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted intracellular proteins
Subcellular location
Nucleoplasm,Nucleoli fibrillar center,Endoplasmic reticulum,Cytosol

OverviewNCBI Gene

This gene encodes a member of the aldo/keto reductase superfamily, which consists of more than 40 known enzymes and proteins. These enzymes catalyze the conversion of aldehydes and ketones to their corresponding alcohols using NADH and/or NADPH as cofactors. The enzymes display overlapping but distinct substrate specificity. This enzyme binds bile acid with high affinity, and shows minimal 3-alpha-hydroxysteroid dehydrogenase activity. This gene shares high sequence identity with three other gene members and is clustered with those three genes at chromosome 10p15-p14. Three transcript variants encoding two different isoforms have been found for this gene. [provided by RefSeq, Dec 2011]

Canonical amino-acid sequenceUniProt

323 residues, UniProt reviewed canonical sequence.

>P52895|AKR1C2
     1  MDSKYQCVKL NDGHFMPVLG FGTYAPAEVP KSKALEAVKL AIEAGFHHID SAHVYNNEEQ
    61  VGLAIRSKIA DGSVKREDIF YTSKLWSNSH RPELVRPALE RSLKNLQLDY VDLYLIHFPV
   121  SVKPGEEVIP KDENGKILFD TVDLCATWEA MEKCKDAGLA KSIGVSNFNH RLLEMILNKP
   181  GLKYKPVCNQ VECHPYFNQR KLLDFCKSKD IVLVAYSALG SHREEPWVDP NSPVLLEDPV
   241  LCALAKKHKR TPALIALRYQ LQRGVVVLAK SYNEQRIRQN VQVFEFQLTS EEMKAIDGLN
   301  RNVRYLTLDI FAGPPNYPFS DEY

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against AKR1C2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Intracellular
Secreted
No
Transmembrane segments
0
Mean surface accessibility (rSASA)
0.23
Highest tissue expression
449 nTPM

Expression across tissuesHPA

Tissue

  • liver: 449 nTPM
  • adipose tissue: 317 nTPM
  • skeletal muscle: 270 nTPM
  • urinary bladder: 234 nTPM
  • breast: 196 nTPM
  • esophagus: 192 nTPM

Single-cell type

  • urothelial cells: 919 nCPM
  • conjunctival goblet cells: 716 nCPM
  • salivary duct cells: 704 nCPM
  • hepatocytes: 562 nCPM
  • foveolar cells: 333 nCPM
  • ocular epithelial cells: 301 nCPM

Immune cell

  • plasmacytoid DC: 0.1 nTPM
  • basophil: 0 nTPM
  • classical monocyte: 0 nTPM
  • eosinophil: 0 nTPM
  • gdT-cell: 0 nTPM
  • intermediate monocyte: 0 nTPM

Brain region

  • medulla oblongata: 30 nTPM
  • pons: 27 nTPM
  • hypothalamus: 27 nTPM
  • thalamus: 25 nTPM
  • midbrain: 19 nTPM
  • spinal cord: 15 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about AKR1C2.

Disease | AllUniProt

Conditions AKR1C2 is implicated in, by any mechanism.

Disease | GeneticClinVar

5 pathogenic / likely-pathogenic of 121 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
1.46
gnomAD pLI
0
gnomAD missense Z
-0.87
DepMap mean gene effect
0.02
DepMap dependency class
none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of AKR1C2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads AKR1C2 as an antibody target. Whether an autoantibody or antibody against AKR1C2 could matter depends on whether native AKR1C2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

AKR1C2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label AKR1C2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/AKR1C2. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

Loading the interactive Seroatlas protein explorer...